4 Places That Offer GLP-1 Microdosing, and What Each One Costs

The 4 GLP-1 microdosing options, one by one

Start with the line that sounds like you:

• Lowest price: Mochi Health, about $140 a month for semaglutide at the lowest dose.
• Small weight goal or keeping weight off: BetterMe Rx, if you can pay a year upfront.
• You want coaching with it: Noom, about $180 a month, billed every 12 weeks.
• Wellness, not weight loss: Fridays, though its benefits are unproven.
• With insurance or Medicare: none of the four. Compounded microdoses are cash only.

Mochi Health: the cheapest microdose, about $140 a month

Mochi Health has a microdosing plan for semaglutide or tirzepatide. It sits next to its standard shots and its weekly semaglutide pill.

Since August 2026, Mochi prices medicine by dose. So the microdose is simply the cheapest step of the same price ladder. Semaglutide medicine starts at about $60 a month. Tirzepatide starts at about $90. The membership adds about $80 a month. Paying a year of membership upfront brings it down to about $50 a month.

Mochi now works as a pharmacy marketplace. You compare partner pharmacies, so these are floor prices that can vary. It suits a first-time user who wants the lowest monthly bill without prepaying. Our Mochi Health review covers its pharmacies and reputation.

BetterMe Rx: a microdose plan for small goals

BetterMe Rx sells a separate microdosing program with compounded semaglutide or tirzepatide shots. It is aimed at losing 5 to 20 pounds or keeping weight off. It also sells daily tablets, which have far less evidence behind them than the shots.

The price stays the same as the dose changes. Visits and shipping are included.

• Semaglutide shot: about $205 a month, or about $145 a month on a 12-month plan paid upfront.
• Tirzepatide shot: about $235 a month, or about $185 a month on the 12-month plan.

Two cautions. Its microdosing page promises weight loss of up to 16% on semaglutide and 22% on tirzepatide. Those are full-dose trial results, not microdose results. And nothing is refunded once an order is processed.

Noom: a microdose with a coaching app

Noom sells a Microdose GLP-1Rx program, separate from its standard $249 GLP-1Rx plan. Noom defines a microdose as 25% or less of a typical maintenance dose. It still frames the plan around weight loss.

The first four weeks cost $79. After that it is about $180 a month. Noom bills it as one charge of about $535 every 12 weeks, so budget for that lump sum. The coaching app is included, which suits women who want help with habits.

Fridays: microdosing sold for wellness

Fridays has a separate Microdosing section, apart from its weight-loss program. It offers a weekly compounded tirzepatide shot for about $200 a month. It also offers a daily oral semaglutide blend for about $250 a month.

Fridays markets these for energy, focus and metabolic balance, not pounds lost. Its own page says compounded microdose formulas have not been studied for those outcomes. Our Fridays review covers the rest of its program.

All four are online services, not local clinics, so your state matters more than your zip code. Mochi Health and BetterMe Rx serve all 50 states. Noom's GLP-1 plans are not offered in Alabama, Louisiana or Mississippi.

What does GLP-1 microdosing mean?

There is no single definition. Harvard endocrinologist Dr. Jody Dushay wrote in STAT News in May 2026 that there is no agreed definition of microdosing. The word covers at least two different things.

The first is a provider-run plan. A telehealth service prescribes a compounded GLP-1 at a low dose, or keeps you on the early steps of the dose ladder longer. A prescriber supervises it.

The second is a do-it-yourself practice. People split a brand-name pen, stretch a vial over more weeks, or buy a microdosing kit online. They usually want a lower price, fewer side effects, or wellness benefits.

A 2025 Evidation survey of more than 60,000 people found about 1 in 7 injectable GLP-1 users had taken lower doses than approved. More than a third of current microdosers decided their dose without a provider.

What GLP-1 microdosing costs, and why the table is short

A cheapest GLP-1 comparison lists far more providers. This table is short on purpose. Most microdosing happens outside any named, priced product, so it cannot be compared without inventing numbers.

Mochi's microdose is the least like a separate product. It is the low end of its normal per-dose plan. BetterMe Rx, Noom and Fridays built separate microdose plans with their own prices.

None of the four lists lab tests in its price. All four use compounded medicine, made by a pharmacy for one patient. Compounded medicine is not FDA-approved, and the FAQ below explains whether it is legal.

How does a microdosing protocol work?

The FDA-approved Wegovy schedule is the usual reference. It starts at 0.25 mg a week. Over at least 16 weeks, it climbs in four more steps to a 2.4 mg maintenance dose. Since March 2026, a stronger 7.2 mg pen called Wegovy HD sits above that. Our semaglutide dosage guide shows every step.

A provider-run microdose usually means staying on the lowest steps longer, or for good. The label treats those steps as starting doses for getting used to the drug, not as maintenance doses.

Noom puts a number on it: 25% or less of a typical maintenance dose. Mochi's semaglutide runs from 0.22 mg to 6.48 mg a week, and its microdose sits at the bottom. In every legitimate version, a prescriber sets and adjusts the dose.

Does the science back microdosing?

Not yet. In the same STAT News piece, Dr. Dushay wrote that there are no legitimate long-term data behind microdosing GLP-1s.

The key trials behind these drugs tested full maintenance doses. They are STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide. In SURMOUNT-1, higher doses brought more weight loss. Staying well below the approved dose is not what either trial tested.

One registered clinical trial is studying microdosed semaglutide for health and longevity. A telehealth company, AgelessRx, runs it, and it has posted no results. Until real results appear, claims that microdosing works rest on stories and marketing.

Is a lower dose gentler, and does it still work?

The gentler pitch makes sense on paper. It may not hold in practice. Endocrinologist Dr. Ritu Anand told Hackensack Meridian Health in May 2026 that microdosing can backfire.

Her point: with each new small dose, it is as if you start over. Side effects can come back full force, in a cycle of ups and downs. On a standard schedule, they usually fade over time.

Marketing claims deserve caution too. In May 2026, the National Advertising Division, the ad industry's watchdog, ruled on Noom's slogan "A Smaller Dose. A Smarter Start." It found the health benefit the slogan implied was not backed up. It asked Noom to change or drop it.

On results, expect less and less predictable. The weight loss in the big trials was measured at maintenance doses. Some people do notice appetite or weight changes at low doses. How much benefit holds at a fraction of the dose is not well studied.

Can GLP-1 microdosing help autoimmune or inflammatory conditions?

This is the part of the trend that deserves the most doubt. GLP-1 receptors exist on immune cells. In animal and lab studies, these drugs lowered inflammation markers such as TNF-alpha and IL-6.

That is real lab science. It is a long way from treating rheumatoid arthritis, lupus or Hashimoto's in people. No completed human trial shows that GLP-1 microdosing improves an autoimmune or inflammatory disease.

Fridays, the brand that leans hardest on wellness language, says so itself. Its page states its compounded microdose formulas have not been studied for those outcomes. When the seller says a claim is unstudied, believe it.

Is microdosing a good start in perimenopause?

Perimenopause can already bring nausea and bloating. So starting lower and slower is appealing. A gentler start may mean fewer of the early nausea spells that make some women quit.

Slower weight loss may also be easier on muscle. That matters when falling estrogen already erodes lean mass. Our guide to GLP-1 and muscle loss in perimenopause covers that trade-off.

The counterweight: staying low trades some certainty about results for comfort. If real weight or metabolic change is the goal, a standard climb to the maintenance dose has stronger evidence. A slower climb to that same dose is a middle path.

How to tell a legitimate low-dose plan from a DIY red flag

What matters most is who manages the dose. A legitimate plan comes from a licensed prescriber and a named compounding pharmacy. Your provider sets the dose and can change it.

Red flags look different. You split a brand-name pen yourself. You buy a microdosing kit from an unnamed seller. You draw your own doses from a vial without clear instructions.

Eli Lilly says its single-dose Zepbound vials contain no preservative and should not be split. Lilly says to throw away an opened vial, even if medicine is left in it.

The FDA has also issued an alert on compounded semaglutide dosing errors. Most reports involved patients drawing too much from a multi-dose vial. Some injected 5 to 20 times their intended dose. Some needed hospital care.

In March 2026, the FDA sent 30 warning letters to telehealth companies over misleading claims about compounded GLP-1s. A bold claim on a landing page is not FDA evidence. If a seller cannot name its pharmacy or a prescriber who reviewed your history, walk away.